Unicar-Therapy Raises ￥10 Million in Extended Series B Round

(VCBeat) Mar. 31, 2021 -- On March 30, 2021, Shanghai Unicar-Therapy Biomed-Pharmaceutical Technology Co., Ltd. ("Unicar-Therapy"), focusing on the development of innovative CAR-T 2.0 therapies, announced that it has extended the Series B investment round by an additional ￥10 million, led by Deguan Capital with participation from Kaizheng Investment. 

The funds raised will be used to advance clinical trials for Unicar-Therapy's first CAR-T 2.0 product, ssCART-19 injection, apply for IND and clinical trials for several new products, and develop and validate novel candidates for solid tumors. In the future, Unicar-Therapy will continue to focus on the development of the next generation of CAR-T technology and safer cancer treatments.

Unicar-Therapy was founded in February 2015. It is one of the first biotechnology companies in China to develop, transform and industrialize the new generation of immunology in cell and gene therapies and related products.

At present, Unicar-Therapy has independently developed a number of  CAR-T products for the treatment of blood tumors. After more than 5 years of clinical verification of a large number of cases, the company successfully obtained the formal clinical trial approval of the first CAR-T 2.0 product -- ssCART-19, in September 2020 , which is the world's first injection for CAR-T therapy of central nervous system leukemia. This clinical trial is currently being carried out in the First Affiliated Hospital of Suzhou University. 

In addition to the hematological oncology R&D pipeline, Unicar-Therapy is also actively engaged in solid tumor immunotherapy, including the introduction of global leading-edge antibody screening and antibody engineering technology platform, and the development and industrialization of other immunotherapies.